# A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

> **NCT06465329** · PHASE2 · RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 120 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Cemiplimab
- **DRUG:** Platinum-based chemotherapy
- **DRUG:** REGN7075

## Key facts

- **NCT ID:** NCT06465329
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-18
- **Primary completion:** 2027-05-20
- **Final completion:** 2030-05-02
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06465329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06465329, "A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06465329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*